Abstract: METHODS: The sequences of the pre-S region and the BCP (A1762T, G1764A) and PC (G1896A) mutations were determined in 46 HBV chronic carriers (CC) and 106 age-matched carriers with different stages of liver diseases, including 38 chronic hepatitis (CH), 18 cirrhosis (LC), and 50 hepatocellular carcinoma (HCC).
Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients.
Abstract: Apart from core promoter A1762T/G1764A and precore G1896A mutations, other hepatitis B virus (HBV) mutants are detected in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB).
Abstract: Triple core promoter mutations T1753C/A1762T/G1764A [corrected] appeared to be linked to genotype C rather than genotype B HBV (19.2%vs 1.9%; P = 0.013).
Sequential accumulation of the basal core promoter and the precore mutations in the progression of hepatitis B virus-related chronic liver disease.
Abstract: The A to T mutation at nucleotide 1762 and/or G to A mutation at nucleotide 1764 were found in 30% in HBeAg(+) ASC, 65.7% in inactive HBsAg carrier, 95% in chronic hepatitis B, and 90% in liver cirrhosis (p < 0.001).
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection.
Abstract: Precore (G1896A) and core-promoter (A1762T/G1764A) mutations were more frequent in patients with fulminant than acute self-limited hepatitis (53% vs.
Abstract: In in vitro transfection experiments, the replication of Bj clone was markedly enhanced by introducing either G1896A or A1762T/G1764A mutation.
Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
PMID: 16928212
2006
Journal of gastroenterology and hepatology
Abstract: Core promoter mutations were seen in five of eight (62.5%) and in six of nine (66.6%); classic double mutations (A1762T/G1764A) of core promoter region were detected in two and three patients and novel double mutations of core promoter (G1764T/C1766G) in one patient each of group Ia and Ib patients, respectively.
Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B.
Abstract: One patient presented core-promoter (A1762T/G1764A) and precore stop codon mutations.
High level of hepatitis B virus DNA after HBeAg-to-anti-HBe seroconversion is related to coexistence of mutations in its precore and basal core promoter.
PMID: 15918203
2005
World journal of gastroenterology
Abstract: AIM: G1896A mutation in precore or A1762T/G1764A mutations in basal core promoter are suspected to be responsible for patients with detectable level of HBV DNA in serum after seroconversion from HBeAg to anti-HBe.
Abstract: CONCLUSION: The coexistence of G1896A mutation and A1762T/G1764A mutations is very common, and responsible for the major cases w
Abstract: Coexistence mutations were found in 77.1% (64/83) out of sera with A1762T/G1764A mutations, and in 50.0% (64/128) out of sera with G1896A mutation.
Optimization of competitively differentiated polymerase chain reaction in detection of HBV basal core promoter mutation.
PMID: 15962387
2005
World journal of gastroenterology
Abstract: A1762T/G1764A mutant was detected in 41.8% (51/122) of patients with HBV infection, but not detected in controls with negative HBsAg.
Abstract: METHODS: Recombinant plasmid of double point mutation A1762T/G1764A in basal core promoter of HBV constructed by site-directed mutagenesis was used as mutant control.
Abstract: Optimized CD-PCR was evaluated by detecting A1762T/G1764A mutation in recombinant plasmids and clinical sera from patients with HBV infection.
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
Abstract: Core promoter': the double basic core promoter (A1762T/G1764A) variant was detected in seven of eight (87%) of group A and in one of five (20%; P=0.03) of group B1 and one of nine (11%; P=0.002) of group B2 patients.
Early response to interferon alpha treatment and long-term clinical outcome in Japanese patients with chronic HBV genotype C infection.
PMID: 14654974
2004
International journal of molecular medicine
Abstract: 92%) and a higher frequency of core promoter mutation (A1762T/G1764A).
HBV mutation literature information.
PMID: 
2006
Gastroenterology
Browser Board
Co-occurred Entities
Filtrator
ViMRT